GILEAD SCIENCES SL
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients
Phase 1
Completed
- Conditions
- HIV InfectionsCondyloma Acuminata
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT00002327
- Locations
- ๐บ๐ธ
Dr Brad Bowden, Houston, Texas, United States
๐บ๐ธPacific Med Ctr, Seattle, Washington, United States
๐บ๐ธHouston Clinical Research Network, Houston, Texas, United States
The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients
Phase 1
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT00002396
- Locations
- ๐บ๐ธ
San Francisco Gen Hosp, San Francisco, California, United States
๐บ๐ธJohns Hopkins Hosp, Baltimore, Maryland, United States
๐บ๐ธUniv of Washington / AIDS Clinical Trial Unit, Seattle, Washington, United States
A Study of PMPA in HIV-Infected Patients
Phase 1
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT00002180
- Locations
- ๐บ๐ธ
Johns Hopkins Univ, Baltimore, Maryland, United States
๐บ๐ธSan Francisco Gen Hosp / AIDS Program, San Francisco, California, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath